<DOC>
	<DOC>NCT00250432</DOC>
	<brief_summary>Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)</brief_summary>
	<brief_title>A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis, Invasive</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>Clinical and Laboratory evidence of blood stream &amp;/or systemic candida infections Possible candida contamination Candida colonization (non invasive infection), urine, cardiac, bone or brain and prosthetic device infections Acute or moderately severe liver disease Abnormal liver function tests Abnormal blood clotting for patients on blood thinners</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>